Memorial Sloan Kettering Cancer Center 13F annual report

Memorial Sloan Kettering Cancer Center is an investment fund managing more than $30.3 million ran by Mark Svenningson. There are currently 5 companies in Mr. Svenningson’s portfolio. The largest investments include VanEck ETF Trust and Caribou Biosciences Inc, together worth $23.5 million.

$30.3 million Assets Under Management (AUM)

As of 8th August 2022, Memorial Sloan Kettering Cancer Center’s top holding is 738,500 shares of VanEck ETF Trust currently worth over $20.2 million and making up 66.8% of the portfolio value. Relative to the number of outstanding shares of VanEck ETF Trust, Memorial Sloan Kettering Cancer Center owns more than 0.1% of the company. In addition, the fund holds 609,196 shares of Caribou Biosciences Inc worth $3.31 million. The third-largest holding is Y-Mabs Therapeutics Inc worth $2.89 million and the next is Oric Pharmaceuticals worth $2.7 million, with 602,272 shares owned.

Currently, Memorial Sloan Kettering Cancer Center's portfolio is worth at least $30.3 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Memorial Sloan Kettering Cancer Center

The Memorial Sloan Kettering Cancer Center office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Mark Svenningson serves as the Senior Vice President Finance at Memorial Sloan Kettering Cancer Center.

Recent trades

There are companies that Memorial Sloan Kettering Cancer Center is getting rid of from its portfolio. Memorial Sloan Kettering Cancer Center closed its position in Royalty Pharma plc on 15th August 2022. It sold the previously owned 2,680,644 shares for $96.9 million. Mark Svenningson also disclosed a decreased stake in Caribou Biosciences Inc by approximately 0.1%. This leaves the value of the investment at $3.31 million and 609,196 shares.

One of the smallest hedge funds

The two most similar investment funds to Memorial Sloan Kettering Cancer Center are Centerstar Fund and Kingstown Capital Management L.P.. They manage $30.2 million and $30.2 million respectively.

Mark Svenningson investment strategy

Memorial Sloan Kettering Cancer Center’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Miscellaneous — making up 66.8% of the total portfolio value. The fund focuses on investments in the United States as 60.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 20% of the total holdings value. On the other hand, small-cap stocks make up 20.0% of the portfolio. The average market cap of the portfolio companies is close to $9.13 billion.

The complete list of Memorial Sloan Kettering Cancer Center trades based on 13F SEC filings

These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Royalty Pharma plc	Closed 2,680,644	$96,878,000
VanEck ETF Trust	No change 738,500	$20,220,000	66.82%
Caribou Biosciences Inc	9.64% 609,196	$3,308,000	10.93%
Y-Mabs Therapeutics Inc	11.87% 191,176	$2,892,000	9.56%
Oric Pharmaceuticals, Inc.	No change 602,272	$2,698,000	8.92%
Illumina Inc	64.02% 6,187	$1,141,000	3.77%
No transactions found
Showing first 500 out of 6 holdings